Tedopi: Phase IIb data

Data from a subgroup of 6 HLA-A2-positive stage IIIB/IV NSCLC patients with brain metastases in a Phase IIb trial showed that Tedopi every 3 weeks for 18 weeks followed by every 2-3 months led to a me...